NFKB1 and neoplasm: The aberrant activation of NF-κB is reported in over 50% of CRCs15, and the genetic deletion of IKKβ, which activates NF-κB in epithelial cells, dramatically reduced tumor incidence in a mouse model of colitis-associated cancer16.